Abstract
Liquisolid tablets for dissolution enhancement of a hypolipidemic drug
1Parul Institute of Pharmacy and Research, P.O. Limda, Waghodia-391 760, India 2Sigma Institute of Pharmacy, Bakrol, Ajwa-Nimeta Road, Dist. Vadodara-390 019, India
Correspondence Address:
Naazneen Surti Sigma Institute of Pharmacy, Bakrol, Ajwa-Nimeta Road, Dist. Vadodara-390 019 India E-mail: naazsurti@gmail.com
This investigation was aimed to improve the dissolution rate of the poorly soluble drug lovastatin, by formulating it as a liquisolid compact. Different liquisolid compacts were prepared using mathematical formulae to calculate the required quantities of powder and liquid ingredients to produce acceptably flowable and compressible admixture. Avicel PH 200, Cab-O-Sil, sodium starch glycolate and PEG 400 were employed as carrier, coating material, disintegrant and non-volatile liquid vehicle, respectively. The various drug to liquid and carrier to coating ratio were used to prepare liquisolid compacts. The formulated liquisolid tablets were evaluated for weight variation, hardness, drug content, friability and disintegration time. The in vitro release characteristics of the drug from tablets formulated by direct compression and liquisolid technique were compared in two different dissolution media. The tableting properties of the liquisolid compacts were within the acceptable limits and drug release rates were distinctly higher as compared to directly compressed tablets. The FTIR spectra showed no interaction between drug-excipient and disappearance of the characteristic absorption band of lovastatin in liquisolid formulations could be attributed to the formation of hydrogen bonding between the drug and liquid vehicle, which resulted in dissolution enhancement. Thus, the liquisolid technique was found to be a promising approach for improving the dissolution of a poorly soluble drug like lovastatin.
Full-Text | PDF